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ABSTRACT
Objectives: The present study evaluates the relationship between the expression levels of hormone receptors (HRs), 
Ki-67, p53 and serum cancer antigen 125 (CA125) levels in endometrial cancer and clinicopathological risk factors, and 
determines their prognostic values.
Material and methods: This retrospective study included 49 patients with endometrial cancer whose estrogen receptor (ER) 
and progesterone receptor (PR) Ki-67 and p53 expression levels were determined through immunohistochemical methods, 
and whose preoperative serum CA125 levels were measured. These factors relationship with various clinicopathological 
factors, progression-free survival (PFS) and overall survival (OS) was investigated.
Results: The study included 49 patients with EC with a mean age of 61 ± 10 years. The rate of HR positivity was significantly 
higher in the endometrioid histology group than in the non-endometroid histology group (p = 0.026). A high level of Ki-
67 expression was found to be associated with a non-endometroid histology (p = 0.016), and a high tumor grade (p < 0.001) 
and a high p53 expression were found to be associated with advanced disease stage (p = 0.026). A positive correlation was 
found between p53 and Ki-67, a negative correlation was found between p53 and Ki-67 and the presence of HR. Significant 
relationship was not found between HR status, p53, Ki-67, CA125 and either other clinicopathological risk factors or survival.
Conclusions: While HR positivity indicates favorable clinicopathological prognostic factors, high Ki-67 and high p53 expres-
sion indicate unfavorable ones. However, no direct effect of these factors on prognosis was found in this study.
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INTRODUCTION
Endometrial cancer (EC) is the most common gyneco-
logical cancer in women in developed countries [1] and 
most cases are diagnosed in the early stage [2]. Despite 
high overall survival rate associated with EC, recurrences 
occur in more than 10% of patients with early stage disease 
if adjuvant therapy is not administered [3–5], and some do 
not survive 5 years. Various classification systems have been 
developed to determine the risk of recurrence, to predict 
prognosis and to guide therapy in EC. In the Bokhman clas-
sification, EC is divided into two groups based on histol-
ogy, grade and hormone receptor status. In addition, risk 
stratification systems have been developed that involve 
the International Federation of Gynecology and Obstetrics 
(FIGO) stage, histology, grade and lymphovascular invasion 
(LVI) [2]. Currently, genetic factors are also being investi-
gated as a prognostic factor, although they are relatively 
expensive and are not available at all centers. Imaging 
studies, including magnetic resonance imaging (MRI) and 
F-18 fluorodeoxyglucose (FDG) positron emission tomogra-
phy (PET)/computed tomography (CT), have been found to 
be useful in EC [6], although they do not always determine 
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the final stage of the tumor, the histology, grade or risk class 
accurately. Surgical staging (total hysterectomy, bilateral 
salpingo-oophorectomy and lymph node dissection) is thus 
recommended as part of the initial treatment of EC [7] and 
risk stratification is carried out accordingly. That said, the cur-
rently used risk stratification systems do not always predict 
prognosis accurately, and so additional factors are sought 
to improve the current risk stratification systems. Various 
studies have reported a relationship between the clinico-
pathological characteristics of EC and immunohistochemical 
markers such as Ki-67, p53 and hormone receptors (HR) [8], 
and serum cancer antigen 125 (CA125) [9] levels. These 
inexpensive and easy-to-apply methods have yet to be 
systematically investigated and to be included in the current 
risk stratification systems. 
Objectives
The present study investigates the relationship between 
immunohistochemically detected estrogen receptors (ER), 
progesterone receptors (PR), Ki-67, p53 expressions and 
serum CA125 levels and various clinicopathological risk 
factors and metabolic parameters in preoperative PET/CT 
scans, with a further investigation of the role of immuno-
histochemical factors and serum CA125 levels in predicting 
the prognosis of EC.
MATERIAL AND METHODS
Patients
For this retrospective study, patients diagnosed with EC 
in Tepecik Training and Research Hospital between March 
2012 and January 2016 were reviewed. The following criteria 
were investigated for patients to be included in the study:
1. Undergoing surgical staging for EC (a total hysterec-
tomy, bilateral salpingo-oophorectomy and lymphad-
enectomy); 
2. Evaluating histopathologically tumor diameter, grade, 
histology, LVI, HR, p53 and Ki-67 expressions of EC; 
3. Having preoperative CA125 levels and PET/CT scans.
Forty-nine patients who met all of these conditions 
were included in the study. Surgical stage, grade and 
histology were determined according to the 2009 FIGO 
classification. HR, p53 and Ki-67 expressions were evalu-
ated using immunohistochemical methods. Patients with 
early stage disease and without negative prognostic factors 
(LVI, non-endometrioid histology, tumors other than stage 
1A and grade 1–2 tumors) underwent no treatment other 
than surgery, whereas those with advanced-stage tumors 
and those at risk of recurrent disease received adjuvant 
therapy (chemotherapy and/or radiotherapy). The patients 
were placed on a postoperative follow-up program involv-
ing ultrasonographic assessment and monitorization of 
serum CA125 levels, along with medical history and physical 
examination findings. Pap smears, CT, MRI or PET/CT were 
performed as required. 
Immunohistochemical analysis 
For immunohistochemistry (IHC), Hematoxylin and 
Eosin (HE) staining was used to select appropriate paraf-
fin blocks and to identify the viable tumor areas. IHC was 
performed by the streptavidin biotin peroxidase method. 
Serial five-µm sections were obtained and these slides were 
baked overnight at 60°C, dewaxed in xylene, and hydrated 
with distilled water through decreasing concentrations of 
alcohol. All slides were treated with heat-induced epitope 
retrieval in the microwave (in 10 mM/L citrate buffer, pH 6.0, 
for 20 minutes, followed by cooling at room temperature 
for 20 minutes) and blocked for endogenous peroxidase 
and biotin. Sections were incubated with primary antibod-
ies in an automated system (Autostainer Link 48; Dako) 
for 20–30 minutes (depending on the antibody) at the 
following dilutions: ER (FLEX Monoclonal Mo a Hu Estro-
gen Receptor, Clone 1D5, RTU; Dako) at 1:100; PR (FLEX 
Monoclonal Mouse, X-Hu Progest Recept, Clone PgR 636, 
RTU; Dako) at 1:200; Ki67 (polyclonal, Dako; 1/500 dilution, 
clone Ki67-MIB-1), and p53 (polyclonal, Dako; 1/500 dilu-
tion, clone P53-DO-7). 
Immunohistochemically ER, PR,Ki67 and p53 stained 
sections were examined under light microscope. The per-
centage of ER, PR, Ki-67, and p53- positive cells was evalu-
ated. Positive cells showed brown staining limited exclu-
sively to the nuclei.
In the assessment of HR status, the patients were divided 
into two groups as those testing negative for both ER and 
PR (HR-) and those testing positive for either ER or PR (HR+). 
A tumor staining ≥ 1% was considered to be predictive of 
ER or PR positivity. 
F-18 FDG PET/CT
The images of the patients from the vertex of the skull to 
the thigh were captured using a PHILIPS GEMINI TF 16 Slice 
PET/CT device. The patients received an intravenous injec-
tion of 0.15 mCi/kg F-18 FDG following 6 hours of fasting. 
CT images (140 kV, 100 mAs, 5 mm slice thickness) were 
captured first, followed by PET emission images (1.5 minutes 
per bed position). The maximum standardized uptake value 
(SUVmax) of the primary tumor was recorded and the SU-
Vmean and metabolic tumor volume (MTV) were calculated 
considering 41% of SUVmax as the threshold value. The total 
lesion glycolysis (TLG) value was calculated by multiplying 
the MTV by the SUVmean. 
Survival 
The progression-free survival (the time from the date 
of diagnosis to the date of progression or death due to EC) 
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and overall survival (the time from the date of diagnosis to 
death due to EC or to the date of last follow-up visit) of all 
patients were calculated. 
Statistical Analysis 
In the statistical analysis, p53, Ki-67 and serum 
CA125 levels were considered as continuous variables and 
HR status was considered as a categorical variable. Patients 
with EC were grouped based on various clinicopathological 
factors [grade, histology, FIGO stage, myometrial invasion 
(MI), cervical invasion (CI), LVI, lymph node metastasis 
(LNM), distant metastasis (DM), and tumor size]. p53, Ki-
67, CA125 and HR were compared between the groups 
with a Mann-Whitney U-test. The Spearman’s correlation 
coefficient (Rho) was used to evaluate the correlation be-
tween the PET parameters and p53, Ki-67, CA125 and HR 
status. Kaplan Meier survival curves were drawn for all 
patients. The relationships between p53, Ki-67, CA125, 
age and PFS and OS were evaluated with a Cox regres-
sion analysis. The difference between the HR-negative 
and HR-positive groups in terms of PFS and OS was in-
vestigated with a Log Rank test. A Log Rank test was also 
used for survival analysis of patients grouped according 
to clinicopathological risk factors.
RESULTS
Patients 
The study included 49 patients with EC with a mean age 
of 61±10 years (range 37–83) of which 30 had an endo-
metrioid and 19 had a non-endometrioid (mixed = 10, 
undifferentiated = 4, serous = 2, squamous = 1, clear 
cell = 1 and mucinous carcinoma = 1) histology, 26 had 
grade 1–2 and 23 had grade 3 tumor, and 43 had FIGO stage 
1–2 and 6 had FIGO stage 3-4 disease. Among all patients, 
MI was ≤ 50% in 29 patients, CI was negative in 40 patients, 
LVI was negative in 23 patients, LNM was negative in 46 pa-
tients, DM was negative in 46 patients and tumor diameter 
was ≤ 4 cm in 20 patients. 
Comparison of hormone receptor status, p53, 
Ki-67 and CA125 among the clinicopathological 
groups 
Of the total, three patients tested negative for both ER 
and PR; 43 tested positive for both ER and PR; and three 
tested positive for only PR. In an evaluation of all study pa-
tients, the mean values were 24.6 ± 0.01 (range 0–95) for p53, 
34.6 ± 0.01 (range 5–80) for Ki-67, and 31.2 ± 0.007 (range 
4.4–189.8) IU/mL for CA125. 
Among the patients grouped according to clinico-
pathological characteristics, the rate of HR positivity was 
significantly higher in the endometrioid histology than in 
the non-endometrioid histology group (p = 0.026). The 
mean Ki-67 level was lower in the endometrioid histol-
ogy than in the non-endometrioid histology group 
(p = 0.016) and in grade 1–2 tumors than in grade 3 tumors 
(p < 0.001). The mean p53 level was higher in patients with 
advanced stage EC than in patients with early stage disease 
(p = 0.026). HR status, p53, Ki-67 and CA125 did not differ 
significantly when the patients were grouped according 
to MI, CI, LVI, LNM, DM and tumor diameter (p > 0.05). 
Furthermore, the mean CA125 level did not differ signifi-
cantly with histology, grade or FIGO stage (p > 0.05). The 
results are presented in Table 1. Figures 1 and 2 present 
two sample cases.
Correlation Analysis between the PET 
parameters and hormone receptor status, p53, 
Ki-67 and CA125
In an analysis of the relationship between HR status, 
p53, ki67 and CA125 levels, a significant moderately positive 
correlation was found between p53 and Ki-67 (r = 0.493, 
p < 0.001), while a weak negative correlation was identi-
fied between HR status and p53 (r = –0.294, p = 0.040) and 
Ki-67 (r = –0.295, p = 0.039). No significant correlation was 
found between CA125 and other parameters, nor between 
HR status, p53, Ki-67, CA125 and the PET parameters of the 
primary tumor (SUVmax, SUVmean, MTV and TLG). The results 
of correlation analysis are presented in Table 2.
Survival Analysis
The mean follow-up time was 35.7 ± 1.5 months 
(3–47 months). Disease progression was observed in 12 pa-
tients, and eight patients died during the follow-up period. 
The mean PFS of the patients was 39.2 ± 2.08 months and 
the mean OS was 42.4 ± 1.6 months. 
No significant difference was observed in PFS or OS 
between the HR-positive group and the HR-negative group 
(Tab. 3). No significant relationship was found between p53, 
Ki-67, CA125 levels and PFS and OS (Tab. 4). 
There was a significant difference between OS and PFS 
of patients grouped according to histology, grade, stage, MI, 
CI, LVI, LNM and DM. However, no significant relation was 
found between tumor diameter and OS and PFS. The results 
are presented in Table 5. Furthermore, age was a prog-
nostic factor for both OS (HR = 1.085, p = 0.041) and PFS 
(HR = 1.100, p = 0.012).
Incidental Findings
Preoperative PET/CT revealed hypermetabolic inciden-
tal lesions among our cases diagnosed with endometrial 
cancer. Histopathological diagnoses of those incidental 
lesions were made and presented as interesting cases in 
Figures 3, 4 and 5. 
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DISCUSSION
EC is divided into two groups, type 1 and type 2, based on 
the classification system proposed by Bokhman in 1983. Type 1 
EC refers to a low-grade, HR-positive tumor with an endome-
trioid histology that is often associated with good prognosis 
[10], while type 2 EC refers to a high-grade, HR-negative 
tumor with a non-endometrioid histology that is associated 
with poorer prognosis than type 1 tumors [10]. This clas-
sification system has been considered insufficient, despite 
its benefits in determining prognosis and guiding therapy, 
leading to the development of risk stratification systems that 
take into account such factors as FIGO stage, grade, histology 
and LVI. In our study, a significant relation was found between 
patient age, tumor histology, grade, stage, MI, CI, LVI, LNM 
and DM and OS and PFS in accordance with the literature. 
However, tumor diameter was not a prognostic factor in 
our study. Although some studies have reported that tumor 
diameter has a prognostic value, it has not been included in 
the risk classification system yet [2]. Also we accepted the 
4 cm tumor diameter for the threshold value that may have 
led to different results from the literature.
The present study evaluated the effects of widely avail-
able immunohistochemical analysis of HR status, Ki-67 and 
p53 expression and serum CA125 levels on prognosis, and 
examined whether or not they contribute to the risk clas-
sification system.
Various studies have evaluated the relationship between 
immunohistochemical parameters and clinicopathological 
factors and survival. In a study involving 164 patients with 
EC, Sivridis et al. [11] reported that the loss or ER or PR is 
Table 1. Comparison of HR, p53, ki67 and CA125 values between clinicopathological groups
HR p53 ki67 CA125
n – (n) + (n) P mean ± SE P mean ± SE P mean ± SE p
Histology
Endometroid 30 0 30 0.026* 19.6 ± 4.3 0.151 29.4 ± 4 0.016* 25.9 ± 5.6 0.268
Nonendometroid 19 3 16 32.6 ± 7.4 42.8 ± 4.9 39.6 ± 11.8
Grade
1–2 26 0 26 0.060 18.8 ± 4.9 0.110 24.1 ± 3.6 < 0.001* 27.8 ± 6.4 0.833
3 23 3 20 31.3 ± 6.3 46.5 ± 4.5 35 ± 9.9
FIGO stage
1–2 43 3 40 0.800 20.9 ± 3.8 0.026* 33.4 ± 3.4 0.287 25.6 ± 4.1 0.411
3–4 6 0 6 51.6 ± 4.2 43.3 ± 9.8 71.2 ± 34.2
MI
≤ 50% 29 1 28 0.352 19.8 ± 4.4 0.258 30.6 ± 3.9 0.125 19.7 ± 2.5 0.411
> 50% 20 2 18 31.7 ± 7.3 40.4 ± 5.3 47.8 ± 12.9
CI
No 40 3 37 0.732 24.2 ± 4.1 0.810 34.4 ± 3.8 0.657 26.6 ± 4.9 0.095
Yes 9 0 9 26.6 ± 12.2 35.5 ± 5.8 51.3 ± 22.2
LVI
No 23 1 22 0.630 19.1 ± 5.7 0.093 29.5 ± 4.5 0.114 18.7 ± 2.9 0.107
Yes 26 2 24 29.6 ± 5.5 39.1 ± 4.5 42.2 ± 10.1
LNM
No 46 3 43 0.860 23.9 ± 4 0.650 35 ± 3.4 0.679 29 ± 5.3 1.000
Yes 3 0 3 36.6 ± 23.3 28.3 ± 13 64.3 ± 51.8
DM
No 46 3 43 0.860 23.4 ± 3.9 0.323 34 ± 3.3 0.485 25.1 ± 3.9 0.172
Yes 3 0 3 43.3 ± 26.8 43.3 ± 18.5 123.5 ± 55.7
Tumor diameter
≤ 4 cm 20 1 19 0.788 21.2 ± 5.8 0.426 31.7 ± 4.7 0.578 20 ± 3.3 0.242
> 4 cm 29 2 27 27 ± 5.5 36.6 ± 4.4 38.9 ± 9.2
Total 49 3 46 24.6 ± 0.01 34.6 ± 0.01 31.2 ± 0.007
HR — hormone receptor; CA 125 — cancer antigen 125; MI — myometrial invasion; CI — cervical invasion; LVI —  lymphovascular invasion; LNM — lymph node 
metastasis; DM — distant metastasis; significant values (p < 0.05) are indicated with*
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Table 2. Correlation analysis of HR, p53, ki67, CA125 and PET parameters
HR P53 Ki67 CA125
r p r p r p r p
SUVmax –0.181 0.214 0.031 0.833 0.250 0.083 0.160 0.271
SUVmean –0.181 0.214 0.009 0.949 0.247 0.087 0.169 0.245
MTV –0.036 0.805 0.029 0.843 0.145 0.322 0.220 0.128
TLG –0.114 0.434 0.047 0.746 0.185 0.203 0.227 0.117
HR – –0.294 0.040* –0.295 0.039* –0.030 0.837
P53 –0.294 0.040* – 0.493 < 0.001* 0.109 0.454
Ki67 –0.295 0.039* 0.493 <0.001* – –0.018 0.903
CA125 –0.030 0.837 0.109 0.454 –0.018 0.903 –
HR — hormone receptor; CA125 — cancer antigen 125; SUVmax — maximum standardized uptake value; MTV — metabolic tumor volume; TLG — total lesion glycolysis, 
significant values (p < 0.05) are indicated with*
associated with a non-endometrioid histology, while the 
loss of ER alone is associated with deep MI. The present 
study, however, could identify no significant relationship 
between hormone receptor status and survival. In another 
study involving 86 patients with EC [12], ER status was con-
sidered to be positive if the cytoplasmic estrogen-binding 
protein was ≥ 5 fmol/mg, and PR status was considered to 
be positive if the cytoplasmic progesterone-binding pro-
tein was ≥ 10 fmol/mg. When the patients in their study 
were grouped according to histology, grade and stage, no 
Figure 1. Endometrioid endometrial carcinoma, Figo grade 2; A–B. 
H & E, ×40, ×100; C–D. estrogen receptor (ER) and progesterone 
receptor (PR), strong positivite by immunohistochemistry (DAB, 
×200), E. P53 negative (DAB, ×200), F. Ki67 10% positive (DAB, ×200)
Figure 2. Undifferentiated endometrial carcinoma; A. Partly solid 
and partly gland forming tumor masses infiltrating the myometrium 
(H & E, ×100); B. A few glands were found in this tumor, which was 
predominantly undifferentiated (H & E, ×200); C–D. Expression of 
estrogen receptor (ER) and progesterone receptor (PR) were negative 
(DAB, ×200); E–F. Strong expression of P53 and Ki67 (DAB, ×200)
Table 4. Survival analysis results of p53, ki67 and CA125
Overall survival Progression free survival
p HR p HR
P53 0.622 1.007 0.695 1.005
Ki67 0.685 1.007 0.888 1.002
CA125 0.512 1.005 0.059 1.010
HR — hazard ratio; CA125 — cancer antigen 125
Table 3. Survival analysis of patients grouped according to hormone 
receptors
n OS (months) p PFS (months) p
HR negative 3 34 ± 3.5 0.483 34 ± 3.5 0.388
HR positive 46 35.8 ± 1.6 33.2 ± 1.9
HR — hormone receptor; OS — overall survival; PFS — progression-free 
survival; survivals are shown as mean ± SE in the table
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significant difference was observed in the mean ER and 
the mean PR among the different histological groups, 
whereas a low receptor level was found to be associated 
with high disease grade and advanced disease stage. Sur-
vival was found to be longer in ER-positive patients than in 
ER-negative patients, in PR-positive patients than in PR- pa-
tients, and in ER/PR double-positive patients than in ER/PR 
double-negative patients. In a study of 903 patients with 
grade 1–2 endometrioid EC [13], less than 1% staining in 
the tumor tissue was considered to be a negative reference 
point for ER and PR. A significant relationship has been 
identified between ER and PR negativity and deep MI, ad-
vanced disease stage and presence of LNM. The loss of ER 
and PR was found to be a negative prognostic factor for PFS 
and OS. In a study of 541 patients with EC involving grade 
3 endometrioid carcinoma and serous carcinoma, Köbel et 
al. [14] considered more than 1% nuclear staining in tumor 
cells to be an indication of receptor positivity. When serous 
EC was evaluated separately, the rate of early-stage tumors 
was found to be significantly higher, and LVI positivity was 
found to be significantly lower in PR-positive patients than in 
PR-negative patients. 
Ki-67 is an antibody indicating cellular proliferation that 
is believed to be related to the aggressiveness of a tumor 
[15]. Overexpressions of Ki-67 and p53 that were found to 
be associated with a poor differentiation in a study involv-
ing 144 patients with EC has been suggested to indicate 
tumor aggressiveness [16]. In a study by Canlorbe et al. 
evaluating 69 patients with EC [8], the positivity cut-offs for 
ER, PR, Ki-67 and p53 were reported to be 20%, 50%, 40% 
and 50%, respectively. In their study, ER and PR levels were 
significantly higher in grade 1–2 than in grade 3 EC, while 
Ki67 and p53 levels were significantly lower. In a study of 
82 patients with EC [17], ≥ 10% receptor expression for ER 
and PR positivity was considered to be predictive and a 27% 
cut-off for Ki-67 was used for the grouping of patients. ER 
and PR negativity was found to be associated with high 
grade, advanced stage and deep MI, and high Ki-67 levels 
were found to be associated with deep MI. In their study, 
the rate of recurrence was found to be significantly higher 
among patients exhibiting all three of the ER negativity, PR 
negativity and high Ki-67 level characteristics. 
In a study involving 73 patients with endometrioid car-
cinoma, Nielsen et al. [15] found a correlation between 
Ki-67 level and tumor grade, whereas no correlation was 
found between Ki-67 level and stage or progesterone re-
ceptor status. In another study, Ki-67 levels were found to 
be significantly higher in grade 3 than in grade 1–2 EC, and 
Ki-67 was further identified as an independent prognostic 
factor for survival [18]. Another study of 142 patients with 
EC also found Ki-67 and p53 expression to be independent 
prognostic factors [19]. In a study by Engelsen et al. [20] that 
involved preoperative curettage specimens of 236 patients 
with EC, pathological p53 expression (staining index > 4) 
was found to be associated with a high grade, advanced 
stage and non-endometrioid histology and high Ki-67 
(> 35%) levels. In a study by Yamauchi et al. [21] involving 
35 patients with EC, the presence of LNM was found to be 
significantly higher in p53-positive carcinomas than in nega-
tive carcinomas. Their study found a positive correlation 
between Ki-67 and p53 levels. Another study claimed that 
serum CA125 levels of < 30.0 IU/mL together with > 50% 
positive PR and/or < 40% Ki-67 indicate low risk for LNM [9].
In the present study, the rate of HR-positivity was higher 
in the endometrioid histology than in the non-endometri-
oid histology. Ki-67 levels were found to be higher in the 
Table 5. Survival analysis of patients grouped according to 
clinicopathological risk factors
OS (months) PFS (months)
mean ± SE p mean ± SE p
Histology
Endometroid 44.3 ± 1.3 0.019* 42.7 ± 1.6 0.015*
Nonendometroid 38.1 ± 3.2 32.4 ± 4.1
Grade
1–2 45.5 ± 0.3 0.011* 43.8 ± 1.2 0.018*
3 37.8 ± 3 33.2 ± 3.7
FIGO stage
1–2 44.1 ± 1.3 0.004* 42.6 ± 1.6 < 0.001*
3–4 28.5 ± 6.6 14.1 ± 5.7
MI
≤ 50% 44.1 ± 1.2 0.029* 42.6 ± 1.7 0.025*
> 50% 38.3 ± 3.2 33.1 ± 4
CI
No 43.7 ± 1.5 0.012* 42.4 ± 1.8 < 0.001*
Yes 34.7 ± 4.4 24.2 ± 5.5
LVI
No 45.9 ± 2.5 0.003* 45.3 ± 0.6 0.002*
Yes 33.2 ± 1.7 32.9 ± 3.4
LNM
No 43.5 ± 1.4 0.001* 41.4 ± 1.7 < 0.001*
Yes 20 ± 6.9 6 ± 2.5
DM
No 43.4 ± 1.5 0.002* 41.1 ± 1.8 < 0.001*
Yes 22 ± 3.5 10 ± 3.4
Tumor diameter
≤ 4 cm 43.2 ± 1.8 0.336 41.6 ± 2.4 0.204
> 4 cm 41.1 ± 2.3 36.9 ± 3
OS — overall survival; PFS — progression-free survival; MI — myometrial 
invasion; CI — cervical invasion; LVI — lymphovascular invasion; LNM 
— lymph node metastasis; DM —distant metastasis; significant values 
(p < 0.05) are indicated with*
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Figure 3. A preoperative PET/CT was performed on a 54-year-old case that was diagnosed with endometrioid carcinoma following an endometrial 
biopsy. Rectal wall thickening with increased FDG uptake (SUVmax: 9.8) (A–D; thin arrow) in addition to a hypermetabolic endometrial lesion 
(SUVmax: 19.6) (A, E–G; thick arrow), and a left adrenal lesion (SUVmax: 6.1) (A, H–J; arrow head) were noted upon PET/CT. The case was operated on, 
and the rectal lesion and the left adrenal lesion were diagnosed to be a primary colon adenocarcinoma and a pheochromocytoma, respectively, 
and the presence of three synchronous tumors in one case was noted. The increased FDG uptake, indicated by the dotted arrow (A), was caused by 
radiopharmaceutical contamination
Figure 4. The preoperative PET/CT of a 62-year-old case diagnosed with a mixed endometrial carcinoma revealed an endometrial lesion with 
increased FDG uptake (SUVmax: 20.9) (A–D; arrow head), in addition to an hypermetabolic concentric wall thickness (SUVmax: 20.2) (A, E–G; thick 
arrow) in a segment of the ascending colon measuring approximately 5 cm, and a hypermetabolic polypoid lesion (SUVmax: 6.5) (A, H–J; thin arrow) 
measuring approximately 1 cm in the descending colon. A histopathological evaluation of the case that was operated on revealed a primary 
colonic adenocarcinoma in the ascending colonic lesion and an adenoma with low-grade dysplasia in the polypoid lesion in the descending colon
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non-endometrioid histology group, and grade 3 EC and 
p53 levels were higher in advanced stage disease. A nega-
tive correlation was found between the presence of HR and 
p53 and Ki-67 expression, and a positive correlation was 
found between p53 and Ki-67 expression. No significant 
relationship was found between HR, p53, ki67, CA125 lev-
els and OS and PFS. Previous studies in literature support 
the findings of the present study, although there are also 
studies suggesting otherwise. The heterogeneous patient 
populations in studies may contribute to different results, 
and the authors also consider that different approaches 
to the evaluation of the immunohistochemical methods 
used in the studies may have contributed to the variations 
in results. For example, some studies used a cut-off value 
of < 1% to evaluate the loss of receptor, as in our study, 
whereas others used a cut-value off of < 10%. Furthermore, 
some studies have evaluated ER and PR separately, whereas 
the present study evaluated them in tandem. In addition, 
no standardized cut-off points have been described for the 
evaluation of pathological Ki-67 and p53 expressions, and 
studies have used variable cut-off points. 
CONCLUSIONS
Despite the small number of patients in the present 
study, the findings suggest that HR positivity indicates fa-
vorable clinicopathological prognostic factors, while high 
Ki-67 and high p53 levels indicate unfavorable ones. How-
ever, no direct effect of these factors on prognosis was 
found in this study, and so further prospective studies 
involving a larger number of patients are needed to incor-
porate HR status, p53, Ki-67 and CA125 levels into the risk 
classification system.
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